| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 18.26% | Credit Suisse | $85 → $82 | Maintains | Outperform |
| 06/20/2023 | 48.54% | Loop Capital | $111 → $103 | Maintains | Buy |
| 06/06/2023 | 15.37% | JP Morgan | $87 → $80 | Downgrades | Overweight → Neutral |
| 05/18/2023 | 15.37% | Deutsche Bank | $90 → $80 | Maintains | Buy |
| 05/09/2023 | 31.24% | Credit Suisse | $94 → $91 | Maintains | Outperform |
| 03/13/2023 | 35.56% | Credit Suisse | → $94 | Initiates Coverage On | → Outperform |
| 02/13/2023 | 62.97% | Loop Capital | $98 → $113 | Maintains | Buy |
| 02/13/2023 | 25.47% | JP Morgan | $80 → $87 | Maintains | Overweight |
| 11/16/2022 | 29.8% | Deutsche Bank | $80 → $90 | Upgrades | Hold → Buy |
| 05/17/2022 | 6.72% | Deutsche Bank | $65 → $74 | Maintains | Hold |
| 01/04/2022 | 0.95% | UBS | $75 → $70 | Maintains | Buy |
| 12/03/2021 | 3.84% | Barclays | $70 → $72 | Maintains | Overweight |
| 07/23/2021 | -10.59% | JP Morgan | → $62 | Upgrades | Neutral → Overweight |
| 07/01/2021 | 12.49% | Loop Capital | → $78 | Upgrades | Hold → Buy |
| 05/05/2021 | 5.28% | Northcoast Research | → $73 | Upgrades | Neutral → Buy |
| 11/05/2020 | -29.33% | UBS | $47 → $49 | Maintains | Buy |
| 07/27/2020 | -45.2% | JP Morgan | $33 → $38 | Downgrades | Overweight → Neutral |
| 06/19/2020 | -35.1% | UBS | $38 → $45 | Maintains | Buy |
| 05/12/2020 | -45.2% | UBS | $39 → $38 | Maintains | Buy |
| 04/16/2020 | -53.85% | Deutsche Bank | $23 → $32 | Maintains | Hold |
| 04/03/2020 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 03/31/2020 | -49.52% | SunTrust Robinson Humphrey | $55 → $35 | Maintains | Buy |
| 03/23/2020 | -42.31% | UBS | $41 → $40 | Maintains | Buy |
| 02/07/2020 | -25.01% | UBS | $50 → $52 | Upgrades | Neutral → Buy |
| 11/06/2019 | -35.1% | JP Morgan | $40 → $45 | Downgrades | Overweight → Neutral |
| 10/16/2019 | — | Baird | Downgrades | Outperform → Neutral | |
| 10/10/2019 | -35.1% | UBS | → $45 | Initiates Coverage On | → Neutral |
| 08/13/2019 | -42.31% | JP Morgan | $50 → $40 | Maintains | Overweight |
| 08/05/2019 | -40.87% | Loop Capital | $69 → $41 | Downgrades | Buy → Hold |
| 10/08/2018 | 9.6% | Barclays | → $76 | Initiates Coverage On | → Overweight |
What is the target price for Cabot (CBT)?
The latest price target for Cabot (NYSE: CBT) was reported by Credit Suisse on August 8, 2023. The analyst firm set a price target for $82.00 expecting CBT to rise to within 12 months (a possible 18.26% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cabot (CBT)?
The latest analyst rating for Cabot (NYSE: CBT) was provided by Credit Suisse, and Cabot maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Cabot (CBT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cabot, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cabot was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Cabot (CBT) correct?
While ratings are subjective and will change, the latest Cabot (CBT) rating was a maintained with a price target of $85.00 to $82.00. The current price Cabot (CBT) is trading at is $69.34, which is out of the analyst's predicted range.